Pfizer Inc Cash Flow Conversion Efficiency
Pfizer Inc cash flow conversion efficiency. Based on the latest financial reports, Pfizer Inc (PFIZ34) has a cash flow conversion efficiency ratio of 0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$835.00 Million ≈ $163.84 Million USD) by net assets (R$85.49 Billion ≈ $16.78 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pfizer Inc (2014–2025)
Cash flow conversion efficiency of Pfizer Inc from 2014 to 2025. This chart illustrates how Pfizer Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pfizer Inc stock quote for real-time trading data and today's change.
Pfizer Inc Cash Flow Conversion Ratio Explained
Pfizer Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pfizer Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pfizer Inc ranked by their cash flow conversion efficiency. Also see how much is Pfizer Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Southern Copper Corporation
NYSE:SCCO
|
0.156x |
|
Banco Santander S.A
F:BSDK
|
0.080x |
|
Deutsche Telekom AG
XETRA:DTE
|
0.117x |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
0.127x |
|
AT&T Inc.
NYSE:T
|
0.086x |
|
Hermes International SCA
PA:RMS
|
0.144x |
|
Seagate Technology PLC
NASDAQ:STX
|
0.602x |
|
Welltower Inc
NYSE:WELL
|
0.015x |
Annual Cash Flow Conversion Efficiency for Pfizer Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Pfizer Inc from 2014 to 2025. Review Pfizer Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | R$86.78 Billion ≈ $17.03 Billion |
R$11.71 Billion ≈ $2.30 Billion |
0.135x | -6.33% |
| 2024-12-31 | R$88.50 Billion ≈ $17.36 Billion |
R$12.74 Billion ≈ $2.50 Billion |
0.144x | +6.78% |
| 2023-12-31 | R$89.29 Billion ≈ $17.52 Billion |
R$12.04 Billion ≈ $2.36 Billion |
0.135x | -55.92% |
| 2022-12-31 | R$95.66 Billion ≈ $18.77 Billion |
R$29.27 Billion ≈ $5.74 Billion |
0.306x | -27.50% |
| 2021-12-31 | R$77.20 Billion ≈ $15.15 Billion |
R$32.58 Billion ≈ $6.39 Billion |
0.422x | +85.29% |
| 2020-12-31 | R$63.24 Billion ≈ $12.41 Billion |
R$14.40 Billion ≈ $2.83 Billion |
0.228x | +14.26% |
| 2019-12-31 | R$63.14 Billion ≈ $12.39 Billion |
R$12.59 Billion ≈ $2.47 Billion |
0.199x | -20.14% |
| 2018-12-31 | R$63.41 Billion ≈ $12.44 Billion |
R$15.83 Billion ≈ $3.11 Billion |
0.250x | +5.93% |
| 2017-12-31 | R$71.31 Billion ≈ $13.99 Billion |
R$16.80 Billion ≈ $3.30 Billion |
0.236x | -13.36% |
| 2016-12-31 | R$59.54 Billion ≈ $11.68 Billion |
R$16.19 Billion ≈ $3.18 Billion |
0.272x | +20.34% |
| 2015-12-31 | R$65.00 Billion ≈ $12.75 Billion |
R$14.69 Billion ≈ $2.88 Billion |
0.226x | -5.26% |
| 2014-12-31 | R$71.62 Billion ≈ $14.05 Billion |
R$17.08 Billion ≈ $3.35 Billion |
0.239x | -- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevna… Read more